Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos for FOP.

Asahi Kasei has signed a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures for approximately ...

Boehringer in terms of licensing deals, with a majority of these agreements being oncology or immunology-focused.

Novo Nordisk and Vivtex are to co-develop next-generation oral biologic therapies to treat obesity, diabetes and related ...

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...

Children are protected against fewer diseases as per the new schedule, which the states say will damage public health.

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

Several new guidance documents issued by the FDA are poised to significantly impact the rare disease development landscape.

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.

J&J has received the US FDA approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro to treat ...